Supriya Lifescience (NSE:SUPRIYA) Beta: 1.1931 (As of Jun. 29, 2026)


NSE:SUPRIYA Supriya Lifescience Ltd NSE:SUPRIYA
81 GF Score
Price ₹928.15
GF Value ₹805.85
Valuation Modestly Overvalued
! 8 Warning Signs
View Full Analysis

What is Supriya Lifescience Beta?

Supriya Lifescience NSE:SUPRIYA -2.61% 81 Beta is 1.1931 as of Jun. 29, 2026. GuruFocus rates NSE:SUPRIYA with a GF Score™ of 81/100 and a GF Value™ of ₹805.85 (Modestly Overvalued). The stock has 8 warning signs investors should review.

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2026-06-29), Supriya Lifescience's Beta is 1.1931.


Supriya Lifescience  (NSE:SUPRIYA) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)


Supriya Lifescience Beta Related Terms


Supriya Lifescience Beta Historical Data

* Premium members only.

The historical data trend for Supriya Lifescience's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Supriya Lifescience Beta Chart

Supriya Lifescience Annual Data
Trend Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Beta
Get a 7-Day Free Trial 0.00 0.00 0.00 1.25 1.37

Supriya Lifescience Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.25 0.99 1.05 1.34 1.37

NSE:SUPRIYA vs VRTX, REGN, ALNY: Beta Comparison

For the Biotechnology subindustry, Supriya Lifescience's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Supriya Lifescience Beta vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Supriya Lifescience's Beta distribution charts can be found below:

* The bar in red indicates where Supriya Lifescience's Beta falls into.


NSE:SUPRIYA
81GF Score
Supriya Lifescience Ltd NSE:SUPRIYA
Beta is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Supriya Lifescience Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.

Frequently Asked Questions Learn more about Beta →
What does a Beta of 1.1931 mean?
Supriya Lifescience (NSE:SUPRIYA) has a Beta of 1.1931 as of Jun. 29, 2026. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Supriya Lifescience and its competitors.
Is Supriya Lifescience's Beta too high?
Supriya Lifescience's current Beta is 1.1931. Overall, Supriya Lifescience has a GF Score™ of 81/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Supriya Lifescience's Beta compare to VRTX and REGN?
Supriya Lifescience's Beta of 1.1931 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beta for a Biotechnology company?
A good Beta depends on the Biotechnology industry context. However, Beta should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beta mean?
A high Beta can signal that a stock is expensive relative to its fundamentals. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Supriya Lifescience and its competitors. Supriya Lifescience's current Beta is 1.1931. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Supriya Lifescience stock overvalued right now?
Based on GuruFocus' analysis, Supriya Lifescience (NSE:SUPRIYA) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹805.85, compared to a current price of ₹928.15 — trading 15.2% above its estimated fair value. The current Beta is 1.1931. Supriya Lifescience's overall GF Score™ is 81/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beta calculated?
Beta is calculated from a company's financial statements. For Supriya Lifescience (NSE:SUPRIYA), the current Beta is 1.1931 as of Jun. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Supriya Lifescience (NSE:SUPRIYA) Overvalued in 2026?

Based on GuruFocus' analysis, Supriya Lifescience stock appears to be overvalued. The current stock price of ₹928.15 is trading 15.2% above its estimated GF Value™ of ₹805.85. GuruFocus considers Supriya Lifescience to be Modestly Overvalued.

Key valuation signals for NSE:SUPRIYA:

  • Beta: 1.1931
  • GF Value™: ₹805.85 vs. price of ₹928.15 (15.2% above fair value)
  • GF Score™: 81/100 with 8 warning signs

No single metric tells the full story. See the NSE:SUPRIYA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Supriya Lifescience Business Description

Other Exchanges 543434:India
Address Sonawala Road, 207/208, Udyog Bhavan, Goregaon East, Mumbai, MH, IND, 400063
Supriya Lifescience Ltd is a manufacturer of Active Pharmaceutical Ingredients. It is focused on diverse therapeutic segments such as antihistamines, analgesics, anaesthetics, vitamins, anti-asthmatic, and anti-allergic.
81GF Score

Get the complete analysis for NSE:SUPRIYA

Beta is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹928.15
Price
₹805.85
GF Value